Investors Purchase Large Volume of Put Options on ADMA Biologics (NASDAQ:ADMA)

ADMA Biologics Inc (NASDAQ:ADMA) was the recipient of some unusual options trading activity on Friday. Stock investors acquired 5,039 put options on the stock. This is an increase of approximately 72% compared to the typical daily volume of 2,926 put options.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a research note on Tuesday, December 23rd. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, ADMA Biologics has an average rating of “Buy” and an average price target of $28.50.

Hedge Funds Weigh In On ADMA Biologics

Several large investors have recently made changes to their positions in ADMA. SG Americas Securities LLC acquired a new stake in ADMA Biologics in the 4th quarter valued at approximately $1,099,000. Wealth Enhancement Advisory Services LLC boosted its position in shares of ADMA Biologics by 11.7% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 6,063 shares of the biotechnology company’s stock valued at $117,000 after acquiring an additional 634 shares during the period. Tealwood Asset Management Inc. bought a new stake in shares of ADMA Biologics in the fourth quarter valued at approximately $1,315,000. Avior Wealth Management LLC grew its stake in shares of ADMA Biologics by 65.3% in the fourth quarter. Avior Wealth Management LLC now owns 17,061 shares of the biotechnology company’s stock worth $311,000 after acquiring an additional 6,741 shares during the last quarter. Finally, City Center Advisors LLC bought a new position in ADMA Biologics during the fourth quarter worth $418,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Price Performance

Shares of ADMA Biologics stock opened at $17.95 on Friday. The company has a current ratio of 7.13, a quick ratio of 3.65 and a debt-to-equity ratio of 0.18. The firm has a fifty day simple moving average of $18.04 and a 200-day simple moving average of $17.13. The stock has a market capitalization of $4.27 billion, a price-to-earnings ratio of 20.87 and a beta of 0.47. ADMA Biologics has a 1-year low of $13.50 and a 1-year high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Wednesday, November 5th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.16. The business had revenue of $134.22 million for the quarter, compared to analyst estimates of $131.20 million. ADMA Biologics had a net margin of 42.87% and a return on equity of 36.52%. ADMA Biologics’s revenue was up 12.0% compared to the same quarter last year. During the same period last year, the business posted $0.15 EPS. On average, sell-side analysts expect that ADMA Biologics will post 0.51 earnings per share for the current year.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.